Skip to Main Content

Paper Details

LKB1 drives stasis and C/EBP-mediated reprogramming to an alveolar type II fate in lung cancer.
Nat Commun
4
2022
Author NameAffiliation
Christopher W MurrayStanford University School of Medicine
Janos DemeterStanford University School of Medicine
David M FeldserUniversity of Pennsylvania
David M FeldserAbramson Family Cancer Research Institute, University of Pennsylvania
Peter K JacksonStanford University School of Medicine
Peter K JacksonStanford University School of Medicine
Peter K JacksonStanford University School of Medicine
Peter K JacksonStanford Cancer Institute, Stanford University School of Medicine
Monte M WinslowStanford University School of Medicine
Monte M WinslowStanford University School of Medicine
Monte M WinslowStanford University School of Medicine
Monte M WinslowStanford Cancer Institute, Stanford University School of Medicine
  • 1 - 12

Datasets

Release 1.2